ANDA 207650, held by Pharmobedient. Caspofungin Acetate.
As of Nov 15, 2026, ANDA 207650 (Caspofungin Acetate), held by Pharmobedient, was first approved by FDA on Sep 29, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 29, 2017 | Original application | Approved | None posted |
| Caspofungin Acetate50MG/VIAL · powder;intravenous | Caspofungin Acetate | Discontinued |
| Caspofungin Acetate70MG/VIAL · powder;intravenous | Caspofungin Acetate | Discontinued |
| Feb 24, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 24, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 29, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
